<DOC>
	<DOCNO>NCT00625612</DOCNO>
	<brief_summary>The purpose trial evaluate safety effectiveness one dose strength Denufosol compare placebo patient CF predict FEV1 great equal 75 % less equal 110 % predict .</brief_summary>
	<brief_title>Study Denufosol Tetrasodium Inhalation Solution Patients With Cystic Fibrosis ( CF ) Lung Disease</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Have confirm diagnosis cystic fibrosis Have FEV1 great equal 75 % less equal 110 % predict normal age , gender height Be able reproducibly perform spirometry Be clinically stable least 4 week screen Have abnormal renal liver function Have lung transplant Unable discontinue use hypertonic saline Participated Inspire trial 08108</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>